questionsmedicales.fr
Thérapeutique
Radiothérapie
Radiothérapie : Questions médicales fréquentes
Termes MeSH sélectionnés :
Administration, Intravenous
Diagnostic
5
Radiothérapie
Cancer
Diagnostic médical
Imagerie médicale
Radiothérapie
IRM
Oncologie
Radiothérapie
Médecin spécialiste
Cancer du sein
Cancer de la prostate
Radiothérapie
Radiothérapie
Prévention du cancer
Traitement du cancer
Symptômes
5
Effets secondaires
Radiothérapie
Symptômes
Nausées
Radiothérapie
Effets indésirables
Effets à long terme
Radiothérapie
Santé reproductive
Fatigue
Radiothérapie
Gestion des symptômes
Appétit
Radiothérapie
Effets secondaires
Prévention
5
Prévention du cancer
Radiothérapie
Traitement du cancer
Prévention du cancer
Mode de vie
Santé
Dépistage
Radiothérapie
Prévention du cancer
Vaccins
Prévention du cancer
HPV
Stress
Prévention du cancer
Santé mentale
Traitements
5
Radiothérapie externe
Curiethérapie
Radiothérapie
Chimiothérapie
Radiothérapie
Traitement combiné
Séances de traitement
Radiothérapie
Cancer
Douleur
Radiothérapie
Effets indésirables
Séance de radiothérapie
Radiothérapie
Procédure médicale
Complications
5
Complications
Radiothérapie
Effets indésirables
Cancers secondaires
Radiothérapie
Risques
Prévention
Complications
Suivi médical
Complications
Radiothérapie
Type de cancer
Soins post-traitement
Radiothérapie
Suivi médical
Facteurs de risque
5
Facteurs de risque
Cancer
Radiothérapie
Antécédents médicaux
Radiothérapie
Cancer
Sexe
Radiothérapie
Cancer
Alimentation
Facteurs de risque
Cancer
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Radiothérapie : Questions médicales les plus fréquentes",
"headline": "Radiothérapie : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Radiothérapie : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-03",
"dateModified": "2025-04-28",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Radiothérapie"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Thérapeutique",
"url": "https://questionsmedicales.fr/mesh/D013812",
"about": {
"@type": "MedicalCondition",
"name": "Thérapeutique",
"code": {
"@type": "MedicalCode",
"code": "D013812",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Curiethérapie",
"alternateName": "Brachytherapy",
"url": "https://questionsmedicales.fr/mesh/D001918",
"about": {
"@type": "MedicalCondition",
"name": "Curiethérapie",
"code": {
"@type": "MedicalCode",
"code": "D001918",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.815.150"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Chimioradiothérapie",
"alternateName": "Chemoradiotherapy",
"url": "https://questionsmedicales.fr/mesh/D059248",
"about": {
"@type": "MedicalCondition",
"name": "Chimioradiothérapie",
"code": {
"@type": "MedicalCode",
"code": "D059248",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.815.160"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Chimioradiothérapie adjuvante",
"alternateName": "Chemoradiotherapy, Adjuvant",
"url": "https://questionsmedicales.fr/mesh/D059186",
"about": {
"@type": "MedicalCondition",
"name": "Chimioradiothérapie adjuvante",
"code": {
"@type": "MedicalCode",
"code": "D059186",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.815.160.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Irradiation crânienne",
"alternateName": "Cranial Irradiation",
"url": "https://questionsmedicales.fr/mesh/D016371",
"about": {
"@type": "MedicalCondition",
"name": "Irradiation crânienne",
"code": {
"@type": "MedicalCode",
"code": "D016371",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.815.190"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Irradiation hypophysaire",
"alternateName": "Pituitary Irradiation",
"url": "https://questionsmedicales.fr/mesh/D010910",
"about": {
"@type": "MedicalCondition",
"name": "Irradiation hypophysaire",
"code": {
"@type": "MedicalCode",
"code": "D010910",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.815.190.600"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Irradiation craniospinale",
"alternateName": "Craniospinal Irradiation",
"url": "https://questionsmedicales.fr/mesh/D061888",
"about": {
"@type": "MedicalCondition",
"name": "Irradiation craniospinale",
"code": {
"@type": "MedicalCode",
"code": "D061888",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.815.230"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Radiothérapie par ions lourds",
"alternateName": "Heavy Ion Radiotherapy",
"url": "https://questionsmedicales.fr/mesh/D063193",
"about": {
"@type": "MedicalCondition",
"name": "Radiothérapie par ions lourds",
"code": {
"@type": "MedicalCode",
"code": "D063193",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.815.250"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Protonthérapie",
"alternateName": "Proton Therapy",
"url": "https://questionsmedicales.fr/mesh/D061766",
"about": {
"@type": "MedicalCondition",
"name": "Protonthérapie",
"code": {
"@type": "MedicalCode",
"code": "D061766",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.815.250.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Irradiation hémicorporelle",
"alternateName": "Hemibody Irradiation",
"url": "https://questionsmedicales.fr/mesh/D017619",
"about": {
"@type": "MedicalCondition",
"name": "Irradiation hémicorporelle",
"code": {
"@type": "MedicalCode",
"code": "D017619",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.815.270"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Irradiation ganglionnaire",
"alternateName": "Lymphatic Irradiation",
"url": "https://questionsmedicales.fr/mesh/D015182",
"about": {
"@type": "MedicalCondition",
"name": "Irradiation ganglionnaire",
"code": {
"@type": "MedicalCode",
"code": "D015182",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.815.350"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Radioimmunothérapie",
"alternateName": "Radioimmunotherapy",
"url": "https://questionsmedicales.fr/mesh/D016499",
"about": {
"@type": "MedicalCondition",
"name": "Radioimmunothérapie",
"code": {
"@type": "MedicalCode",
"code": "D016499",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.815.520"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Radiothérapie adjuvante",
"alternateName": "Radiotherapy, Adjuvant",
"url": "https://questionsmedicales.fr/mesh/D018714",
"about": {
"@type": "MedicalCondition",
"name": "Radiothérapie adjuvante",
"code": {
"@type": "MedicalCode",
"code": "D018714",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.815.600"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Dosimétrie en radiothérapie",
"alternateName": "Radiotherapy Dosage",
"url": "https://questionsmedicales.fr/mesh/D011879",
"about": {
"@type": "MedicalCondition",
"name": "Dosimétrie en radiothérapie",
"code": {
"@type": "MedicalCode",
"code": "D011879",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.815.639"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Fractionnement de la dose d'irradiation",
"alternateName": "Dose Fractionation, Radiation",
"url": "https://questionsmedicales.fr/mesh/D019583",
"about": {
"@type": "MedicalCondition",
"name": "Fractionnement de la dose d'irradiation",
"code": {
"@type": "MedicalCode",
"code": "D019583",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.815.639.200"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Hypofractionnement de dose",
"alternateName": "Radiation Dose Hypofractionation",
"url": "https://questionsmedicales.fr/mesh/D000069473",
"about": {
"@type": "MedicalCondition",
"name": "Hypofractionnement de dose",
"code": {
"@type": "MedicalCode",
"code": "D000069473",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.815.639.200.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Hypofractionnement de dose",
"alternateName": "Radiation Dose Hypofractionation",
"url": "https://questionsmedicales.fr/mesh/D000069473",
"about": {
"@type": "MedicalCondition",
"name": "Hypofractionnement de dose",
"code": {
"@type": "MedicalCode",
"code": "D000069473",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.815.639.200.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Radiothérapie de haute énergie",
"alternateName": "Radiotherapy, High-Energy",
"url": "https://questionsmedicales.fr/mesh/D011882",
"about": {
"@type": "MedicalCondition",
"name": "Radiothérapie de haute énergie",
"code": {
"@type": "MedicalCode",
"code": "D011882",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.815.722"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Thérapie par capture de neutrons",
"alternateName": "Neutron Capture Therapy",
"url": "https://questionsmedicales.fr/mesh/D017247",
"about": {
"@type": "MedicalCondition",
"name": "Thérapie par capture de neutrons",
"code": {
"@type": "MedicalCode",
"code": "D017247",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.815.722.500"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Thérapie par capture de neutrons par le bore",
"alternateName": "Boron Neutron Capture Therapy",
"url": "https://questionsmedicales.fr/mesh/D016754",
"about": {
"@type": "MedicalCondition",
"name": "Thérapie par capture de neutrons par le bore",
"code": {
"@type": "MedicalCode",
"code": "D016754",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.815.722.500.100"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Thérapie par capture de neutrons par le bore",
"alternateName": "Boron Neutron Capture Therapy",
"url": "https://questionsmedicales.fr/mesh/D016754",
"about": {
"@type": "MedicalCondition",
"name": "Thérapie par capture de neutrons par le bore",
"code": {
"@type": "MedicalCode",
"code": "D016754",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.815.722.500.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Télégammathérapie",
"alternateName": "Radioisotope Teletherapy",
"url": "https://questionsmedicales.fr/mesh/D011867",
"about": {
"@type": "MedicalCondition",
"name": "Télégammathérapie",
"code": {
"@type": "MedicalCode",
"code": "D011867",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.815.722.820"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Radiothérapie guidée par l'image",
"alternateName": "Radiotherapy, Image-Guided",
"url": "https://questionsmedicales.fr/mesh/D061089",
"about": {
"@type": "MedicalCondition",
"name": "Radiothérapie guidée par l'image",
"code": {
"@type": "MedicalCode",
"code": "D061089",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.815.768"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Radiothérapie X",
"alternateName": "X-Ray Therapy",
"url": "https://questionsmedicales.fr/mesh/D014964",
"about": {
"@type": "MedicalCondition",
"name": "Radiothérapie X",
"code": {
"@type": "MedicalCode",
"code": "D014964",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E02.815.907"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Radiothérapie",
"alternateName": "Radiotherapy",
"code": {
"@type": "MedicalCode",
"code": "D011878",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "David R Raleigh",
"url": "https://questionsmedicales.fr/author/David%20R%20Raleigh",
"affiliation": {
"@type": "Organization",
"name": "Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA. David.Raleigh@ucsf.edu."
}
},
{
"@type": "Person",
"name": "Baolin Qu",
"url": "https://questionsmedicales.fr/author/Baolin%20Qu",
"affiliation": {
"@type": "Organization",
"name": "Precision Medical Advanced Innovation Center, Beijing University of Aeronautics and Astronautics, Beijing, 100083."
}
},
{
"@type": "Person",
"name": "Gustavo Arruda Viani",
"url": "https://questionsmedicales.fr/author/Gustavo%20Arruda%20Viani",
"affiliation": {
"@type": "Organization",
"name": "Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (FMRP-USP), Ribeirão Preto, SP, Brazil."
}
},
{
"@type": "Person",
"name": "P A Coucke",
"url": "https://questionsmedicales.fr/author/P%20A%20Coucke",
"affiliation": {
"@type": "Organization",
"name": "Service de Radiothérapie, CHU Liège, Belgique."
}
},
{
"@type": "Person",
"name": "William C Chen",
"url": "https://questionsmedicales.fr/author/William%20C%20Chen",
"affiliation": {
"@type": "Organization",
"name": "Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, 94143, USA. william.chen@ucsf.edu."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Pharmacokinetics and tolerability of intranasal or intravenous administration of nalbuphine in infants.",
"datePublished": "2022-09-13",
"url": "https://questionsmedicales.fr/article/36100355",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/archdischild-2022-323807"
}
},
{
"@type": "ScholarlyArticle",
"name": "A case of intravenous iron administration resulting in cerebral edema expansion.",
"datePublished": "2023-05-30",
"url": "https://questionsmedicales.fr/article/37254070",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12883-023-03258-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "Feasibility of periprocedural decision on the administration of intravenous contrast media in MRI for endometriosis.",
"datePublished": "2023-06-25",
"url": "https://questionsmedicales.fr/article/37392544",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejrad.2023.110949"
}
},
{
"@type": "ScholarlyArticle",
"name": "Optimization of intravenous administration of hydroxocobalamin in pediatric emergencies - HYDROX-OPTIMIS study.",
"datePublished": "2023-10-21",
"url": "https://questionsmedicales.fr/article/37871551",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ienj.2023.101353"
}
},
{
"@type": "ScholarlyArticle",
"name": "Clinical Administration Characteristics of Subcutaneous and Intravenous Administration of Daratumumab in Patients With Multiple Myeloma at Mayo Clinic Infusion Centers.",
"datePublished": "2023-02-09",
"url": "https://questionsmedicales.fr/article/36758192",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1200/OP.22.00421"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Thérapeutique",
"item": "https://questionsmedicales.fr/mesh/D013812"
},
{
"@type": "ListItem",
"position": 3,
"name": "Radiothérapie",
"item": "https://questionsmedicales.fr/mesh/D011878"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Radiothérapie - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Radiothérapie",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Radiothérapie",
"description": "Comment la radiothérapie est-elle diagnostiquée ?\nQuels examens précèdent la radiothérapie ?\nQui détermine le besoin de radiothérapie ?\nQuels types de cancers nécessitent la radiothérapie ?\nLa radiothérapie est-elle utilisée en prévention ?",
"url": "https://questionsmedicales.fr/mesh/D011878?mesh_terms=Administration,+Intravenous#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Radiothérapie",
"description": "Quels symptômes peuvent apparaître après la radiothérapie ?\nLa radiothérapie cause-t-elle des nausées ?\nY a-t-il des symptômes à long terme ?\nComment gérer la fatigue liée à la radiothérapie ?\nLa radiothérapie affecte-t-elle l'appétit ?",
"url": "https://questionsmedicales.fr/mesh/D011878?mesh_terms=Administration,+Intravenous#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Radiothérapie",
"description": "La radiothérapie peut-elle prévenir le cancer ?\nQuels modes de vie aident à prévenir le cancer ?\nLes dépistages aident-ils à éviter la radiothérapie ?\nLes vaccins peuvent-ils prévenir certains cancers ?\nLe stress influence-t-il le cancer ?",
"url": "https://questionsmedicales.fr/mesh/D011878?mesh_terms=Administration,+Intravenous#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Radiothérapie",
"description": "Quels types de radiothérapie existent ?\nLa radiothérapie est-elle combinée à d'autres traitements ?\nCombien de séances de radiothérapie sont nécessaires ?\nLa radiothérapie est-elle douloureuse ?\nComment se déroule une séance de radiothérapie ?",
"url": "https://questionsmedicales.fr/mesh/D011878?mesh_terms=Administration,+Intravenous#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Radiothérapie",
"description": "Quelles sont les complications possibles de la radiothérapie ?\nLa radiothérapie peut-elle causer des cancers secondaires ?\nComment prévenir les complications de la radiothérapie ?\nLes complications varient-elles selon le type de cancer ?\nQuels soins sont nécessaires après la radiothérapie ?",
"url": "https://questionsmedicales.fr/mesh/D011878?mesh_terms=Administration,+Intravenous#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Radiothérapie",
"description": "Quels sont les facteurs de risque pour le cancer traité par radiothérapie ?\nL'âge influence-t-il le besoin de radiothérapie ?\nLes antécédents médicaux influencent-ils la radiothérapie ?\nLe sexe joue-t-il un rôle dans le traitement par radiothérapie ?\nL'alimentation affecte-t-elle le risque de cancer ?",
"url": "https://questionsmedicales.fr/mesh/D011878?mesh_terms=Administration,+Intravenous#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment la radiothérapie est-elle diagnostiquée ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "La radiothérapie n'est pas diagnostiquée, mais elle est prescrite après un diagnostic de cancer."
}
},
{
"@type": "Question",
"name": "Quels examens précèdent la radiothérapie ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens d'imagerie comme le scanner ou l'IRM sont souvent réalisés avant la radiothérapie."
}
},
{
"@type": "Question",
"name": "Qui détermine le besoin de radiothérapie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un oncologue est responsable de l'évaluation et de la prescription de la radiothérapie."
}
},
{
"@type": "Question",
"name": "Quels types de cancers nécessitent la radiothérapie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "La radiothérapie est couramment utilisée pour les cancers du sein, de la prostate et du poumon."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle utilisée en prévention ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la radiothérapie est un traitement curatif, pas préventif, pour les cancers diagnostiqués."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent apparaître après la radiothérapie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, rougeur de la peau et douleurs localisées selon la zone traitée."
}
},
{
"@type": "Question",
"name": "La radiothérapie cause-t-elle des nausées ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des nausées peuvent survenir, surtout si la zone traitée est l'abdomen ou le cerveau."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes à long terme ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets à long terme peuvent inclure des changements cutanés ou des problèmes de fertilité."
}
},
{
"@type": "Question",
"name": "Comment gérer la fatigue liée à la radiothérapie ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est conseillé de se reposer, de bien s'hydrater et de suivre les conseils du médecin."
}
},
{
"@type": "Question",
"name": "La radiothérapie affecte-t-elle l'appétit ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains patients peuvent éprouver une perte d'appétit pendant le traitement."
}
},
{
"@type": "Question",
"name": "La radiothérapie peut-elle prévenir le cancer ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la radiothérapie est un traitement, pas un moyen de prévention du cancer."
}
},
{
"@type": "Question",
"name": "Quels modes de vie aident à prévenir le cancer ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation saine, l'exercice régulier et l'évitement du tabac peuvent aider à prévenir le cancer."
}
},
{
"@type": "Question",
"name": "Les dépistages aident-ils à éviter la radiothérapie ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dépistages réguliers peuvent détecter le cancer tôt, réduisant ainsi le besoin de radiothérapie."
}
},
{
"@type": "Question",
"name": "Les vaccins peuvent-ils prévenir certains cancers ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des vaccins comme celui contre le HPV peuvent prévenir certains cancers, comme le cancer du col de l'utérus."
}
},
{
"@type": "Question",
"name": "Le stress influence-t-il le cancer ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress n'est pas un facteur direct, mais un mode de vie sain peut aider à réduire le risque."
}
},
{
"@type": "Question",
"name": "Quels types de radiothérapie existent ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux types sont la radiothérapie externe et la radiothérapie interne (curiethérapie)."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle combinée à d'autres traitements ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est souvent combinée avec la chimiothérapie ou la chirurgie pour une efficacité accrue."
}
},
{
"@type": "Question",
"name": "Combien de séances de radiothérapie sont nécessaires ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le nombre de séances varie selon le type de cancer, généralement entre 5 et 30 séances."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle douloureuse ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la radiothérapie elle-même n'est pas douloureuse, mais des effets secondaires peuvent l'être."
}
},
{
"@type": "Question",
"name": "Comment se déroule une séance de radiothérapie ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le patient est positionné sur une table, et des rayons ciblés sont administrés sans douleur."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles de la radiothérapie ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent inclure des lésions tissulaires, des infections et des effets secondaires à long terme."
}
},
{
"@type": "Question",
"name": "La radiothérapie peut-elle causer des cancers secondaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il existe un risque faible de développer des cancers secondaires après une radiothérapie."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications de la radiothérapie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier et le respect des recommandations du médecin aident à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Les complications varient-elles selon le type de cancer ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent varier selon la localisation et le type de cancer traité."
}
},
{
"@type": "Question",
"name": "Quels soins sont nécessaires après la radiothérapie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des soins de la peau, une bonne hydratation et un suivi médical sont essentiels après le traitement."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour le cancer traité par radiothérapie ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent le tabagisme, l'exposition à des substances cancérigènes et des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le besoin de radiothérapie ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de cancer augmente avec l'âge, ce qui peut nécessiter une radiothérapie."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils la radiothérapie ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de cancer ou de radiothérapie peuvent influencer le traitement futur."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans le traitement par radiothérapie ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines cancers sont plus fréquents chez un sexe, influençant ainsi le besoin de radiothérapie."
}
},
{
"@type": "Question",
"name": "L'alimentation affecte-t-elle le risque de cancer ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en fruits et légumes peut réduire le risque de certains cancers."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 28/04/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA. David.Raleigh@ucsf.edu.
Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA. David.Raleigh@ucsf.edu.
Publications dans "Radiothérapie" :
2 publications dans cette catégorie
Affiliations :
Precision Medical Advanced Innovation Center, Beijing University of Aeronautics and Astronautics, Beijing, 100083.
Department of Radiotherapy, PLA General Hospital, Beijing, 100853.
Publications dans "Radiothérapie" :
2 publications dans cette catégorie
Affiliations :
Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (FMRP-USP), Ribeirão Preto, SP, Brazil.
Publications dans "Radiothérapie" :
2 publications dans cette catégorie
Affiliations :
Service de Radiothérapie, CHU Liège, Belgique.
Publications dans "Radiothérapie" :
2 publications dans cette catégorie
Affiliations :
Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, 94143, USA. william.chen@ucsf.edu.
Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, 94143, USA. william.chen@ucsf.edu.
Publications dans "Radiothérapie" :
2 publications dans cette catégorie
Affiliations :
Department of Pathology, Johns Hopkins University, Baltimore, MD, 21287, USA.
Publications dans "Radiothérapie" :
2 publications dans cette catégorie
Affiliations :
Department of Radiation Oncology, Ohio State University, Columbus, OH, 43210, USA.
Publications dans "Radiothérapie" :
2 publications dans cette catégorie
Affiliations :
Department of Neurological Surgery, Northwestern University, Chicago, IL, 60611, USA.
Publications dans "Radiothérapie" :
2 publications dans cette catégorie
Affiliations :
Department of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Jiangsu 404100, China.
Publications dans "Radiothérapie" :
2 publications dans cette catégorie
Affiliations :
Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Münster, Gebäude A1, Albert Schweitzer Campus, 48149, Münster, Deutschland. hans.eich@ukmuenster.de.
Publications dans "Radiothérapie" :
2 publications dans cette catégorie
Affiliations :
Department of Radiation Oncology, The Mayo Clinic, Rochester, MN, USA.
Publications dans "Radiothérapie" :
2 publications dans cette catégorie
Affiliations :
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Publications dans "Radiothérapie" :
1 publication dans cette catégorie
Affiliations :
University Hospital for Tumors, Sestre milosrdnice University Hospital Center.
Publications dans "Radiothérapie" :
1 publication dans cette catégorie
Affiliations :
Department of Radiation Oncology, University of Rochester, Rochester, NY 14642, USA.
Publications dans "Radiothérapie" :
1 publication dans cette catégorie
Affiliations :
Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA 90095, USA.
Publications dans "Radiothérapie" :
1 publication dans cette catégorie
Affiliations :
Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Publications dans "Radiothérapie" :
1 publication dans cette catégorie
Affiliations :
Department of Radiation Oncology, University of Rochester, Rochester, NY 14642, USA.
Publications dans "Radiothérapie" :
1 publication dans cette catégorie
Affiliations :
Department of Radiation Oncology, University of Rochester, Rochester, NY 14642, USA.
Publications dans "Radiothérapie" :
1 publication dans cette catégorie
Affiliations :
Dept. of Radiation Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University.
Publications dans "Radiothérapie" :
1 publication dans cette catégorie
Affiliations :
Department of Liver Surgery and Liver Transplantation, State Key Laboratory of Biotherapy and Cancer Center, Sichuan University and Collaborative Innovation Center of Biotherapy, West China Hospital, Chengdu, Sichuan 610000, P.R. China.
Publications dans "Radiothérapie" :
Intranasal nalbuphine could be a safe, efficacious and non-invasive alternative to parenteral pain medication in infants. We aimed to assess pharmacokinetics (PK) and tolerability of intranasal and in...
Prospective open-label study including infants 1-3 months of age admitted to the emergency department, receiving nalbuphine for procedural pain management. Patients were alternately allocated to a sin...
Out of 52 study subjects receiving nalbuphine, 31 were eligible for NCA (11 intravenous, 20 intranasal). Median AUC...
This is the first study investigating intranasal administration of nalbuphine in infants suggesting an intranasal bioavailability close to 50%. Non-invasive intranasal application was well tolerated. ...
NCT03059511....
Iron plays an important role in the development of perihematomal edema (PHE) in the setting of intracerebral hemorrhage (ICH). Cerebral iron is increased via direct hemoglobin release in ICH, and seve...
A 46-year-old woman was admitted to the hospital with acute moderate-to-severe TBI. Her head computed tomography (CT) scan showed bifrontal hemorrhagic contusions with mild PHE. She was started on hyp...
We believe this is the first report of exacerbating PHE accompanied by clinical decline after intravenous iron administration in the setting of acute hemorrhagic brain contusions. Though the effects o...
To assess the feasibility of a periprocedural decision on the administration of intravenous contrast media in MRI for endometriosis and to evaluate the frequency and reasons of contrast administration...
In this retrospective, descriptive cross-sectional single-center study all patients were included, who received a pelvic MRI for evaluation of endometriosis between April 2021 and February 2023. Frequ...
303 consecutive patients (mean age, 33.4 years +/- 8.3 [standard deviation]) were evaluated. Periprocedural decision on the administration of intravenous contrast media had been made in all cases. For...
A periprocedural decision on the administration of contrast media in MRI for endometriosis is feasible with little effort. It allows the administration of contrast media to be avoided in most cases. I...
Procedures to prepare and infuse intravenous drugs are poorly documented....
To determinate the optimal mode of hydroxocobalamin administration in children in emergency care....
We identified three modes of administration: (1) connect infusion tubing to the vial, start the infusion and interrupt it when the desired dose has been delivered; (2) remove from the vial the volume ...
25 nurses performed each of these three procedures for children weighting 15 and 30 kg. Speed and precision were primary end-points; ease, safety and drug economy were secondary end-points....
Mode 3 was the fastest (42[37-61] sec) followed by modes 1 and 2 (p < 0.05). Mode 3 was the most precise (100[100-100]%) followed by modes 1 and 2 (p = 0.001). Mode 3 was the easiest (10.0[9.0-10.0]) ...
Taking the required volume from the vial and infuse directly was the fastest, the most precise, the easiest and most economical mode of administration. It should be recommended....
Median duration of daratumumab (DARA) administration for treatment of multiple myeloma is 3-7 hours for the intravenous formulation (DARA IV) and 3-5 minutes for the subcutaneous formulation (DARA SC)...
Time-based measurements were extracted using a scheduling/pharmacy software program that tracked patient movement through appointments for patients initiating DARA in Mayo Clinic infusion centers from...
Median total clinic times were 2.7-3.0 hours shorter for DARA SC versus DARA IV. Median clinic times were highest at dose 1 and decreased with subsequent doses. Median total chair times were 2.7-2.8 h...
Reduced clinic times were observed with DARA SC, indicating that use of DARA SC as a treatment option results in time savings that may free clinic resources. Furthermore, novel methods of electronic h...
Guidelines recommend an analgesia-first strategy for sedation during mechanical ventilation, but associations between opioids provided during mechanical ventilation and posthospitalization opioid-rela...
To evaluate associations between an intravenous opioid dose received during mechanical ventilation and postdischarge opioid-related outcomes in medical (nonsurgical) patients....
This retrospective cohort study evaluated adults receiving mechanical ventilation lasting 24 hours or more for acute respiratory failure and surviving hospitalization. Participants from 21 Kaiser Perm...
Terciles of median daily intravenous fentanyl equivalents during mechanical ventilation....
The primary outcome was the first filled opioid prescription in 1 year after discharge. Secondary outcomes included persistent opioid use and opioid-associated complications. Secondary analyses tested...
The study included 6746 patients across 21 hospitals (median age, 67 years [IQR, 57-76 years]; 53.0% male). Of the participants, 3114 (46.2%) filled an opioid prescription in the year prior to admissi...
In this retrospective cohort study of patients receiving mechanical ventilation, opioids administered during mechanical ventilation were associated with opioid prescriptions following hospital dischar...
Contrast-associated AKI may result in higher morbidity and mortality. Intravenous fluid administration remains the mainstay for prevention. There is a lack of consensus on the optimal administration s...
We conducted a secondary analysis of 4671 PRESERVE participants who underwent angiographic procedures. Although fluid type was randomized, strategy of administration was at the discretion of the clini...
The mean (SD) age was 70 (8) years, 94% of participants were male, and median (interquartile range) eGFR was 60 (41-60) ml/min per 1.73 m...
We found that administration of a total volume of 1000 ml, starting at least 1 hour before contrast injection and continuing postcontrast for a total of 6 hours, is associated with a similar risk of a...
The metabolism of lufotrelvir, a novel phosphate prodrug of PF-00835231 for the treatment of COVID-19, was evaluated in healthy human volunteers and clinical trial participants with COVID-19 following...
Vedolizumab is a humanized monoclonal antibody, indicated for the treatment of moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD), that specifically binds to the α4β7 integr...
Sixteen participants received a single IV infusion of vedolizumab (300 mg). Blood samples were collected to measure vedolizumab serum concentrations. The safety of all subjects was monitored....
The pharmacokinetic analysis showed that vedolizumab reached the maximum observed serum concentration (C...
Vedolizumab was well tolerated in healthy Chinese subjects when administered as a single-dose IV 300 mg infusion. In this study, the rate of AVA positivity was 37.5%, which occurred near the end of th...
http://www.chinadrugtrials.org.cn : CTR20171528....
The benefits and risks of the intraosseous (IO) route for vascular access in patients with out-of-hospital cardiac arrest (OHCA) remain controversial. This study compares the success rates of establis...
This was a retrospective study conducted by the San-Min station of Taoyuan Fire Department. Data for IV access were collected between January 1, 2020, and December 31, 2020. Data for IO access were co...
A total of 112 adult patients were enrolled in the analysis, including 71 men and 41 women, with an average age of 67 years. There were 90 IV access cases and 22 IO access cases. The groups were compa...
The IO route was significantly associated with higher success rates of route establishment, epinephrine administration, and shorter time-to-epinephrine in the prehospital resuscitation of adult patien...